Researchers have harnessed the power of digital health records to achieve insight into the potential of inflammation-controlling drugs to reduce a patient’s Alzheimer’s illness risk.
Informatics and director of the Center for Artificial Intelligence in Drug Discovery at Case Western Reserve University; Mark Gurney, chairman and CEO of Tetra Therapeutics; and David Kaelber, chief medical informatics officer and vice chairman of Health Informatics at The MetroHealth System, accessed almost two decades of electronic health records from the IBM Watson Healthcare Explorys Cohort Discovery platform. The researchers analyzed the de-recognized data from 56 million unique grownup patients from 26 well being-care systems throughout the U.S.
The big, retrospective case-control research discovered that the chance for Alzheimer’s disease in patients being handled with adalimumab (Humira) for rheumatoid arthritis and in sufferers treated with etanercept (Enbrel) or adalimumab for psoriasis was lower than the general population risk.
The researchers wanted to check the speculation that systemic inflammation involving tumor necrosis factor (TNF) is associated with an elevated risk for Alzheimer’s disease (AD), and that treating sufferers who had inflammation with a TNF-blocking agent would be efficient in reducing a person’s risk for developing AD.
Sufferers for the study had been drawn from the Explorys platform and categorized based on their inflammatory illness diagnoses and drug history.